Artiva Biotherapeutics, Inc. (ARTV:NASDAQ) closed at $4.01 on November 13, 2026, up 1.26% on the day. The stock trades 72.4% below its 52-week high of $14.53 and 35.5% above its 52-week low of $2.96. Over the past year, it gained 14.2%. Artiva Biotherapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, ARTV closed higher on 124 days (49%). Its best day was December 15, 2025 (+90.91%) and its worst was October 27, 2026 (-30.68%). The stock moved 10% or more in a single session 20 times. It opened at least 5% above the previous day's high 3 times.
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Find more stocks like ARTV with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.